BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32061458)

  • 1. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer.
    Sahni S; Moon EA; Howell VM; Mehta S; Pavlakis N; Chan D; Ahadi MS; Gill AJ; Samra J; Mittal A
    Eur J Surg Oncol; 2020 Aug; 46(8):1539-1542. PubMed ID: 32061458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
    Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
    Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
    HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
    Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
    Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
    Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
    Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
    Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
    Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
    J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Yako YY; Kruger D; Smith M; Brand M
    PLoS One; 2016; 11(5):e0154016. PubMed ID: 27170998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEACAM7 expression contributes to early events of pancreatic cancer.
    Dhasmana A; Dhasmana S; Kotnala S; Laskar P; Khan S; Haque S; Jaggi M; Yallapu MM; Chauhan SC
    J Adv Res; 2024 Jan; 55():61-72. PubMed ID: 36828119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma.
    Nissen NI; Kehlet S; Johansen AZ; Chen IM; Karsdal M; Johansen JS; Diab HMH; Jørgensen LN; Sun S; Manon-Jensen T; He Y; Langholm L; Willumsen N
    Int J Cancer; 2021 Jul; 149(1):228-238. PubMed ID: 33687786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.
    Yang KS; Im H; Hong S; Pergolini I; Del Castillo AF; Wang R; Clardy S; Huang CH; Pille C; Ferrone S; Yang R; Castro CM; Lee H; Del Castillo CF; Weissleder R
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
    Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
    Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.
    Jiang K; Tan E; Sayegh Z; Centeno B; Malafa M; Coppola D
    Appl Immunohistochem Mol Morphol; 2017 Oct; 25(9):620-623. PubMed ID: 27093451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
    Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
    Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.